DaVita Inc. generated $12.82 billion in FY2024 revenue as one of the largest providers of kidney care services in the world, operating 2,657 outpatient dialysis centers in the United States serving 200,800 patients and 509 centers in 13 countries serving 80,300 patients. The Denver-based company, founded in 1999 through the merger of Total Renal Care and Renal Treatment Centers, employs approximately 71,000 people and provides 29.05 million dialysis treatments annually.
DaVita: Key Facts
- Founded: 1999 (modern entity)
- Headquarters: Denver, Colorado
- CEO: Javier Rodriguez (appointed 2019)
- FY2024 Revenue: $12.82 billion
- FY2024 Net Income: $936.3 million
- Market Capitalization: Approximately $12.3 billion (June 2026)
- Employees: Approximately 71,000
- US Centers: 2,657
- US Patients: 200,800
- Stock Listing: NYSE (DVA)
- CIK: 0000927066
How Does DaVita Make Money?
DaVita generates revenue primarily by providing dialysis services to patients with end-stage renal disease. In FY2024, dialysis patient service revenues were $12.26 billion (95.7% of total revenue). The company provided 29.05 million treatments at an average of 92,534 treatments per day, with revenue per treatment of $391.32. The payer mix is critical: Medicare and Medicaid account for 67% of US dialysis revenue ($8.21 billion) but generate thin margins, while commercial insurance contributes 33% ($4.05 billion) but generates approximately 70-80% of profitability because commercial rates are 3-4x Medicare rates.
Who Founded DaVita and When?
DaVita was formed in 1999 through the merger of Total Renal Care and Renal Treatment Centers. The company was renamed DaVita—Italian for 'giving life.' Kent Thiry was recruited as CEO in 1999 and transformed the struggling company through operational discipline and the $3.5 billion Gambro acquisition in 2005. In 2012, DaVita acquired HealthCare Partners for $4.42 billion to diversify into physician services, but sold this business to Optum in 2019 for approximately $4.9 billion, returning focus to kidney care.
What Is DaVita's Competitive Advantage?
DaVita's primary competitive advantage is its position in the US dialysis duopoly with Fresenius Medical Care, controlling approximately 80% of the market. This scale creates barriers to entry through economies of scale in purchasing, standardized clinical protocols, and nephrologist relationships. The company's 2,657 US centers create a dense network that reduces patient travel time. Commercial payer negotiations leverage this market position to secure rates 3-4x Medicare levels. The Integrated Kidney Care platform manages 71,300 patients in risk-based arrangements, positioning DaVita as a care coordinator beyond traditional dialysis.
How Has DaVita's Revenue Grown Over Time?
DaVita's revenue has grown from approximately $3 billion in 2000 to $12.82 billion in 2024. FY2024 revenue of $12.82 billion represented 5.6% growth from $12.14 billion in 2023, driven by higher average revenue per treatment and international expansion. The 2005 Gambro acquisition more than doubled revenue, while the 2012 HealthCare Partners acquisition added approximately $3 billion before its 2019 sale. Management guides to 2025 adjusted operating income of $2.01–$2.16 billion and adjusted EPS of $10.20–$11.30.
DaVita Business Model Explained
DaVita operates a facility-based dialysis delivery model that generates revenue through per-treatment reimbursement from government and commercial payers. The company invests approximately $555 million annually in capital expenditures for center development and equipment, while generating $2.02 billion in operating cash flow. DaVita's cost structure is dominated by patient care costs ($258.12 per treatment, 66% of revenue per treatment), with general and administrative expenses and depreciation representing additional costs. The company uses leverage strategically—carrying $9.51 billion in debt—to fund growth while returning capital to shareholders through aggressive share repurchases ($1.38 billion in 2024). The leverage ratio is 3.03x consolidated EBITDA, within the covenant maximum of 5.00x.
DaVita Key Acquisitions
DaVita's acquisition history reflects the consolidation of the US dialysis market. The 2005 Gambro acquisition ($3.5 billion) transformed DaVita into a national competitor to Fresenius. The 2012 HealthCare Partners acquisition ($4.42 billion) was a failed diversification into physician services that was sold to Optum in 2019 for $4.9 billion. International acquisitions have expanded the footprint to 509 centers in 13 countries. The company has focused on tuck-in acquisitions and international expansion rather than transformative deals since the HealthCare Partners divestiture.
What Are the Biggest Risks Facing DaVita?
DaVita's biggest risks include commercial payer pressure reducing the 3-4x rate premium over Medicare; Medicare reimbursement cuts affecting 67% of revenue; federal policy promoting home dialysis and transplants that could reduce in-center volume; high leverage with $9.51 billion in debt and $470.5 million in annual interest expense; patient mortality and volume volatility; labor costs and workforce shortages for dialysis nurses and technicians; and regulatory risks including antitrust scrutiny of the dialysis duopoly and state-level staffing initiatives.
Bottom Line
DaVita is growing, with FY2024 revenue up 5.6% to $12.82 billion and operating income of $2.09 billion. The company's position in the dialysis duopoly, scale advantages, and commercial payer profitability support strong cash flow generation. However, the extreme payer mix concentration—with commercial patients generating 70-80% of profit at only 33% of volume—creates vulnerability to any shift in commercial rates or mix. The $9.51 billion debt load amplifies these risks. Management's 2025 guidance assumes stable commercial mix, flat treatment volumes, and successful cost management. DaVita must navigate the transition from volume-based dialysis provider to value-based kidney care company while maintaining the profitability that supports aggressive share repurchases and Berkshire Hathaway's investment thesis.
